ArticleJournal of nanobiotechnology2026
Mitochondria-targeted nanozyme hydrogel remodels the microenvironment to enhance bone regeneration in diabetes-associated periodontitis.
Article in Journal of nanobiotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Diabetes-associated periodontitis is a multifactorial disease driven by metabolic disorders and chronic inflammation, featuring mitochondrial dysfunction, excessive reactive oxygen species (ROS), and impaired bone metabolism that collectively impair tissue regeneration. To modulate this pathological microenvironment, we developed an intelligent therapeutic system integrating antioxidation, mitochondrial targeting, and regeneration. The Mn-Zn-tannic acid@SS31 (MZT@S) nanozyme was encapsulated within a PLGA-PEG-PLGA (PPP) thermosensitive hydrogel to obtain MZT@S/PPP. MZT@S exhibits superoxide dismutase-like and catalase-like activities, which enable efficient elimination of ROS. In addition, the mitochondria targeting peptide SS31 enhances mitochondrial localization of the nanozyme and thereby promotes mitochondria-derived ROS scavenging and restores mitochondrial oxidative phosphorylation. The injectable hydrogel allows rapid in situ gelation and provides sustained local release. The MZT@S/PPP hydrogel restores mitochondrial function, promotes osteogenesis and angiogenesis, and induces macrophage M2 polarization, thereby re-establishing immune homeostasis. In vivo, the system suppresses alveolar bone loss and enhances new bone formation in diabetes-associated periodontitis, leading to a markedly improved inflammatory and regenerative microenvironment. This multifunctional hydrogel represents a promising strategy for precise treatment of diabetes-associated periodontitis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.